Latest by Barbara Jungwirth
High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.
Use of the dapivirine vaginal ring for pre-exposure prophylaxis (PrEP) does not lead to resistance mutations in women who seroconvert, Urvi Parikh, Ph.D., reported at the HIV Research for Prevention 2018 conference.
The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
A quadrivalent mosaic HIV vaccine induced greater immune responses on a variety of assays and against several HIV clades than its trivalent equivalent, as reported at the 2018 HIVR4P conference.
Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.
HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.
Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...
The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.
How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.